CORONA REMEDIES
Back to Income Statement
|
CORONA REMEDIES Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Consolidated Net Profit | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
What is the latest Consolidated Net Profit of CORONA REMEDIES ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2026 | ₹149 Cr |
| Mar2025 | ₹905 Cr |
| Mar2024 | ₹85 Cr |
| Mar2023 | ₹85 Cr |
How is Consolidated Net Profit of CORONA REMEDIES Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹149 Cr | -83.49 | |
| Mar2025 | ₹905 Cr | 965.63 | |
| Mar2024 | ₹85 Cr | 0.00 | |
| Mar2023 | ₹85 Cr | - | |
Compare Consolidated Net Profit of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹13,551.5 Cr | -1.7% | 3.5% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹448,196.0 Cr | -0.4% | -3.3% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹250,390.0 Cr | 0.4% | 9.9% | 55.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,967.0 Cr | -3.4% | -4.2% | 37.1% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | 0.5% | -3.2% | -12.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,329.0 Cr | 0.9% | 0% | -11% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | -1.7% |
3.5% |
|
| SENSEX | 0.1% |
-2.7% |
-8.6% |
You may also like the below Video Courses